Reportlinker Adds Merck KGaA: PharmaVitae Profile

NEW YORK, April 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Merck KGaA: PharmaVitae Profile

http://www.reportlinker.com/p0186215/Merck-KGaA-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector

*Learn how the continued strong performance of Erbitux will drive the company's prescription pharma business in the period to 2015

*Evaluate the company's more focused business strategy and see how its extensive restructuring has affected its operating cost and profit margins

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Merck KGaA: PharmaVitae forecasts at a glance 7

Strategic insight 8

Erbitux and Serono acquisition rejuvenate branded Rx pharma business... 8

...and diversify Merck KGaA's portfolio to improve long-term prospects 9

From pure-play small molecule company to biopharmaceutical 10

Expansion into CNS and oncology 11

Breaking into the US 12

A 'younger' product portfolio 13

Re-structuring bolsters financial performance 14

SWOT analysis 17

Strengths 17

Growth prospects of Erbitux 17

Broad portfolio supported by pipeline 18

Continued sales growth from off-patent products 18

Weaknesses 18

Over reliance on Erbitux to drive growth 18

Opportunities 19

Expansion of oncology portfolio through continued growth of Erbitux and development of pipeline candidates 19

Continued improvement of operating profit margin 19

Use high revenues to pursue licensing deals to further bolster portfolio 20

Pursue M&A opportunities to build consumer health and life sciences businesses 20

Threats 20

Increasing competition from biosimilars is affecting the growth prospects of Merck KGaA's therapeutic protein franchise 20

CHAPTER 3 QUARTERLY NEWS UPDATE 25

Product developments 25

Deals and alliances 26

Product deals 26

Technology deals 31

M&A activity 33

Company announcements 34

Future product milestones 38

CHAPTER 4 COMPANY INTRODUCTION 39

Key findings 39

Background 40

Key corporate developments 40

M&A history 41

Merck-Serono Biopharmaceuticals 41

Divestment of generics business 41

Streamlined focus 42

Current corporate structure 42

Pharmaceuticals 43

Branded prescription pharmaceuticals 43

Consumer health 43

Chemicals 44

Performance & life science chemicals 44

Liquid crystals 44

Pharmaceuticals business unit structure 45

CHAPTER 5 COMPANY SALES 46

Key findings 46

Prescription pharmaceutical sales and growth rate analysis, 2001-13 48

Product analysis 50

Product analysis, 2001-07 50

Product analysis, 2007-13 53

Therapy area analysis 56

Therapy area analysis, 2001-07 57

Therapy area analysis, 2007-13 59

Therapy area focus, 2001-13 61

Geographic analysis 63

Geographic analysis, 2001-07 64

Geographic analysis, 2007-13 66

Geographic focus, 2001-13 68

Launch/core/expiry analysis 69

Explanation of launch/core/expiry analysis 69

Launch analysis, 2007-13 70

Core analysis, 2007-13 71

Expiry analysis, 2007-13 72

Launch/core/expiry configuration, 2007-13 73

Molecule type analysis 75

Molecule type analysis, 2001-07 76

Molecule type analysis, 2007-13 77

Externalization analysis 79

Externalization analysis, 2001-07 80

Externalization analysis, 2007-13 81

CHAPTER 6 COMPANY FINANCIALS 83

Key findings 83

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 84

Financial statements, 2001-07 86

Profit and loss account, 2001-07 86

Balance sheet, 2001-07 88

Operating costs and profit analysis 90

Operating costs and profit analysis, 2001-07 91

Operating cost ratio and profit margin analysis, 2001-07 92

Operating cost ratio and profit margin analysis, 2007-13 93

Operating costs and profit analysis, 2007-13 95

Return on capital employed analysis 97

Capital employed analysis, 2001-07 98

Return on capital employed (RoCE) analysis, 2001-07 100

Market capitalization analysis 103

Market capitalization analysis, 2001-07 103

Total shareholder returns analysis, 2001-07 104

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 106

Key findings 106

Overview 107

CNS 108

Rebif 108

Overview 108

Sales forecast 109

Mylinax 113

Overview 113

Sales forecast 114

safinamide 117

Overview 117

Sales forecast 118

Oncology 121

Erbitux 121

Overview 121

Sales forecast 122

Cardiovascular 124

Concor & Concor-Plus 124

Overview 124

Sales forecast 125

Kuvan 126

Overview 126

Sales forecast 127

Urology & gender-specific health 128

Gonal-F 128

Overview 128

Sales forecast 129

Endocrine, metabolic and genetic disorders 132

Glucophage & Glucovance 132

Overview 132

Sales forecast 133

CHAPTER 8 APPENDIX 134

R&D pipeline 134

References 135

Papers 135

Company releases 135

Datamonitor reports 135

News articles 136

Abbreviations 136

Exchange rates 137

List of Tables

Table 1: Merck KGaA - PharmaVitae forecasts at a glance 7

Table 2: Merck KGaA key product developments, Q1 2008-Q1 2009 25

Table 3: Merck KGaA product deals and alliances, Q1 2008-Q1 2009 26

Table 4: Merck KGaA technology deals and alliances, Q1 2008-Q1 2009 31

Table 5: Merck KGaA M&A activity, Q1 2008-Q1 2009 33

Table 6: Merck KGaA company announcements, Q1 2008-Q1 2009 34

Table 7: Merck KGaA future product milestones, 2009-10 38

Table 8: Merck KGaA, product portfolio overview ($m), 2001-07 50

Table 9: Merck KGaA, product portfolio overview ($m), 2007-13 53

Table 10: Merck KGaA, therapy portfolio overview ($m), 2001-07 57

Table 11: Merck KGaA, therapy portfolio overview ($m), 2007-13 59

Table 12: Merck KGaA, portfolio overview by geographic region ($m), 2001-07 64

Table 13: Merck KGaA portfolio overview by geographic region ($m), 2007-13 66

Table 14: Merck KGaA launch portfolio overview ($m), 2007-13 70

Table 15: Merck KGaA core portfolio overview ($m), 2007-13 71

Table 16: Merck KGaA expiry portfolio overview ($m), 2007-13 72

Table 17: Merck KGaA portfolio overview by molecule type ($m), 2001-07 76

Table 18: Merck KGaA product portfolio overview by molecule type ($m), 2007-13 77

Table 19: Merck KGaA product portfolio overview by source ($m), 2001-07 80

Table 20: Merck KGaA product portfolio overview by source ($m), 2007-13 81

Table 21: Total Merck KGaA sales by business unit ($m), 2001-07 84

Table 22: Merck KGaA profit and loss account ($m), 2001-07 86

Table 23: Merck KGaA balance sheet ($m), 2001-07 88

Table 24: Merck KGaA operating revenue/cost analysis ($m), 2001-07 91

Table 25: Merck KGaA operating cost ratio analysis (% of total revenues), 2001-07 92

Table 26: Merck KGaA operating cost ratio analysis (% of total revenues), 2007-13 93

Table 27: Merck KGaA operating revenue/cost analysis ($m), 2007-13 95

Table 28: Merck KGaA capital employed ($m), 2001-07 98

Table 29: Merck KGaA EBIT return on capital employed ($m), 2001-07 100

Table 30: Merck KGaA EBIT pre-tax return/capital employed driver analysis (%), 2001-07 101

Table 31: Merck KGaA market capitalization ($ billion), 2001-07 103

Table 32: Merck KGaA total shareholder returns (annual %), 2001-07 104

Table 33: Key products overview 107

Table 34: Rebif: overview 108

Table 35: Rebif: sales forecast ($m), 2007-13 109

Table 36: Mylinax: overview 113

Table 37: Mylinax: sales forecast ($m), 2007-13 114

Table 38: safinamide: overview 117

Table 39: safinamide: sales forecast ($m), 2007-13 118

Table 40: Erbitux: overview 121

Table 41: Erbitux: sales forecast ($m), 2007-13 122

Table 42: Concor & Concor-Plus: overview 124

Table 43: Concor & Concor-Plus: sales forecast ($m), 2007-13 125

Table 44: Kuvan: overview 126

Table 45: Kuvan: sales forecast ($m), 2007-13 127

Table 46: Gonal-F: overview 128

Table 47: Gonal-F: sales forecast ($m), 2007-13 129

Table 48: Glucophage & Glucovance: overview 132

Table 49: Glucophage & Glucovance: sales forecast ($m), 2007-13 133

Table 50: Merck KGaA's R&D pipeline (Phase I-registration) 134

Table 51: Exchange rates, 2007 137

List of Figures

Figure 1: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5

Figure 2: Merck KGaA's financial performance ($m), 2001-13 6

Figure 3: Merck KGaA's externalization, growth drivers ($m), 2001-13 9

Figure 4: Merck KGaA's biologics focus (percentage of branded ethical sales), 2001, 2006 and 2007 10

Figure 5: Merck KGaA's therapeutic focus (percentage of branded ethical sales), 2001, 2006 and 2007 11

Figure 6: Merck KGaA's geographic focus (percentage of branded ethical sales), 2001, 2006 and 2007 12

Figure 7: Merck KGaA's age of products (percentage of branded ethical sales), 2001, 2006 and 2007 13

Figure 8: Merck KGaA's restructuring and its effects on operating margins, 2001-08e 15

Figure 9: Merck KGaA SWOT analysis 17

Figure 10: Current corporate structure 42

Figure 11: Merck KGaA, business unit focus (% total sales), 2001-07 43

Figure 12: Merck KGaA, pharmaceuticals business units sales ($m), 2001-08e 45

Figure 13: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 48

Figure 14: Merck KGaA key sales growth driver & resistors ($m), 2001-07 51

Figure 15: Merck KGaA key sales growth drivers & resistors ($m), 2007-13 54

Figure 16: Merck KGaA prescription pharmaceutical sales by therapy area ($m), 2001-13 56

Figure 17: Merck KGaA prescription pharma sales by therapy area (% of total), 2001-13 61

Figure 18: Merck KGaA prescription pharmaceutical sales by geographic region ($m), 2001-13 63

Figure 19: Merck KGaA growth drivers and resistors by geographic region ($m), 2001-07 64

Figure 20: Merck KGaA drivers and resistors by geographic region ($m), 2007-13 66

Figure 21: Merck KGaA prescription pharmaceutical sales by geographic region (% of total), 2001-13 68

Figure 22: Merck KGaA launch/core/expiry configuration ($m), 2007-13 73

Figure 23: Merck KGaA prescription pharmaceutical sales by molecule type ($m), 2001-13 75

Figure 24: Merck KGaA growth drivers and resistors by molecule type ($m), 2007-13 78

Figure 25: Merck KGaA prescription pharmaceutical sales by source ($m), 2001-13 79

Figure 26: Merck KGaA growth drivers and resistors by source ($m), 2001-07 80

Figure 27: Merck KGaA growth drivers and resistors by source ($m), 2007-13 82

Figure 28: Merck KGaA operating revenue/cost analysis ($m), 2001-13 90

Figure 29: Merck KGaA operating cost ratio analysis (% of total revenues), 2001-13 94

Figure 30: Merck KGaA return on capital employed, EBIT margin and capital turnover, 2001-07 97

Figure 31: Return on capital employed formula 101

Figure 32: Merck KGaA market capitalization ($ billion), 2001-07 104

Figure 33: Merck KGaA total shareholder returns vs. S&P 500 ($m), 2001-07 105

Figure 34: Multiple sclerosis market position of the leading four disease-modifying therapies across the seven major markets, 2007 110

To order this report:

Pharmaceutical Industry: Merck KGaA: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo